Bruce Levine, Ph.D. 🇺🇦

Frontiers | Multiplex engineering using microRNA-mediated gene silencing in CAR T cells Multiplex gene edited CAR T cell therapies face challenges, including potential oncogenic risks from double-strand breaks. Targeted microRNAs (miRNAs) may of...

🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation www.frontiersin.org/journals/imm...

More disease coming, unfortunately in kids. Adults making the bad decisions for them.

YouTube video by The Stem Cell Channel from The Niche 5 reasons not to go to a stem cell clinic

My new 2-minute 5-point short on why one shouldn't go to stem cell clinics or at least seriously weigh risks + low chance of benefit. Good little video for scientists and physicians too looking for clear explanation when people ask #stemcells #stemcell www.youtube.com/shorts/EX9iU...

New analysis predicts sprawling effects of proposed NIH budget cuts Initial analyses of the Trump administration’s proposed NIH cuts neglect key aspects of their long-term economic and health impact, study says.

Cutting NIH to “save” money is fundamentally flawed
-Modest annual savings pale compared to multi‑trillion‑dollar health, innovation, and productivity losses www.statnews.com/2025/07/28/n...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

There should be a cable channel fact checking all the cable news channels and their paid "pundits" in real time

If gifted narrative filmmaker Marwin Gansauge asks, "Can I make a movie about you?", what do you say? More than ever, science communication is desperately needed to convey the importance of research in developing new treatments for patients. Filmed in Vancouver & Dublin youtu.be/YrevpY-DNmw

Is Makary's FDA already heading toward a breaking point? - The Niche Stem cell biologist writes about how Makary's FDA is already in serious trouble due to politics and a lack of experienced staff.

Is Makary's FDA already heading toward a breaking point? ipscell.com/2025/07/is-m... #stemcells #stemcell #CRISPR what does it mean for the cell and gene therapy field?

Pandemic Revisionism, Part One: COVID-19 Origins Because people keep getting this very wrong.

How did the pandemic start?

I have avoided publicly commenting on this for 5 years. Here's my take as someone who has no stake at all in the game.

gidmk.substack.com/p/pandemic-r...

If real facts matter to you

Sign of the times.

A well-placed biotech investor says U.S. policies are straining life sciences startups A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.

A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.
www.statnews.com/2025/07/15/b...

Taxing innovation

TFW when UFC is valued > MIT is not AOK

🧵3/3 Academia and industry form powerful partnerships for impact @pennmedicine.bsky.social
Since 2018, the Penn Medicine Co-Investment program has spurred faculty innovation, created jobs, and scaled up ideas into large-scale clinical studies. pennmedicine.org/news/academi...

🧵2/3 How future cures begin as ideas in laboratories
The successes of CAR T research show the importance of the cycle of science
@PennMedicine
—sparking new ideas and clinical trials that give patients better options. pennmedicine.org/news/how-fut...

🧵1/3 How discoveries become cures, in a virtuous cycle
@pennmedicine.bsky.social
- Public investments in biomedical research have an outsized effect, driving new scientific insights, economic growth, and ultimately treatments and cures. #NIH pennmedicine.org/news/how-dis...

🏋️Training Course! The Use of Cell Therapies for Autoimmune Diseases: CAR-T in #Paris Oct 16-17
#immunotherapy #autoimmune #Tcell #tcellrx @isctglobal.bsky.social
www.isctglobal.org/workforce-de...

What vaccine skepticism brings👇

World’s Premier Cancer Institute Faces Crippling Cuts and Chaos - KFF Health News After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%.

After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%. kffhealthnews.org/news/article...

World’s premier cancer institute faces crippling cuts and chaos | CNN The Trump administration’s broadsides against scientific research have caused unprecedented upheaval at the National Cancer Institute, the storied federal government research hub that has spearheaded ...

🚨Worse than you think "World’s premier cancer institute faces crippling cuts and chaos" There used to be bipartisan support. Now:
-Rat on your colleagues
-Silencing the science communicators
-A budget to ‘destroy clinical research’
#NCI #NIH #Cancer #cancerresearch
www.cnn.com/2025/07/08/h...

Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia - Nature Biomedical Engineering An ex vivo organotypic and immunocompetent human leukaemia chip system is used for CAR T cell therapy modelling and screening of patient response.

Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. #Tcell #immunotherapy #organonachip 🧪https://www.nature.com/articles/s41551-025-01428-2

There is arguably no compelling proposed mechanism of action whereby specific cells could reasonably be expected to be effective, i.e. cord blood for autism

In vivo CAR T cell generation to treat cancer and autoimmune disease Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity f...

The Capstan Therapeutics team is exceptional. This is just the beginning of transforming the delivery of CAR T cell immunotherapies www.science.org/doi/10.1126/...

🚨🚨🚨Big news for development of in vivo CAR T cells: AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion @abbvie @capstantx #TCell #tcellrx #immunotherapy www.streetinsider.com/Corporate+Ne...

Too many people recognize their opinions as feelings, but mistake their beliefs for facts.

Closed minds hold truths to be self-evident. Open minds are willing to question even strongly held views.

Lifelong learning requires the courage to challenge our own convictions.

Private sector, philanthropy can’t replace science cuts. #NIH #CDC #FDA #Science www.statnews.com/2025/06/26/n... via
@statnews.com

Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn The U.S. may be headed for a “choose your own adventure” approach to vaccine policy, in which skeptical parents follow the guidelines that confirm their beliefs.

Unbridled individualism at the expense of community safety and #misinformation on vaccines threatens lives www.statnews.com/2025/06/24/v... via @statnews.com